Clinical and molecular basis of transfusion-induced immunomodulation: Summary of the proceedings of a state-of-the-art conference

Transfusion Medicine Reviews

Volumn 15, Issue 2, 2001, Pages 108-135

  Blajchman, Morris A ^a,b,c,d,e   Dzik, Sunny ^a,b,c,d,e   Vamvakas, Eleftherios C ^a,b,c,d,e   Sweeney, Joseph ^a,b,c,d,e   Snyder, Edward L ^a,b,c,d,e  

^a MCMASTER UNIVERSITY   (Canada)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MIRIAM HOSPITAL   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD TRANSFUSION; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; INFECTION; LEUKOCYTE; MEDICAL EDUCATION; MEDICAL LITERATURE; MOLECULAR DYNAMICS; NONHUMAN; REVIEW; TUMOR GROWTH;

EID: 0035048822     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1053/tmrv.2001.22614     Document Type: Review

References (85)

1. Apoptosis in transfusion medicine: Of death and dying-is that all there is?
2. Nuclear matrix protein is released from apoptotic white blood cells during cold (1-6C) storage of concentrated red blood cell units and might induce antibody response in multiply transfused patients
3. White cell apoptosis in platelet concentrates
4. T lymphocytes and the adaptive immune response
5. Leukocyte reduction of blood components: Public policy and new technology
6. Immunomodulation by blood transfusion: An evolving scientific and clinical challenge
7. Blood transfusion and total joint replacement surgery: T helper 2 cytokine secretion and clinical outcome
8. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery
9. Randomized controlled trial comparing transfusion of leukocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer
10. Randomized comparison of leukocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery
11. Beneficial effect of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: A randomized clinical trial
12. Randomized trial comparing packed red blood cell transfusion with and without leukocyte depletion for gastrointestinal surgery
13. Modifying risk for extracorporeal circulation: Trial of four anti-inflammatory strategies
14. Cost-effectiveness of blood transfusion and white cell reduction in elective colorectal surgery
15. A cost analysis of autologous and allogeneic transfusion in hip replacement surgery
16. Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery
17. The clinical advantages of autologous transfusion: A randomized, controlled study after knee replacement
18. Allogeneic versus autologous blood during abdominal aortic aneurysm surgery
19. Blood transfusions and prognosis in colorectal center
20. Transfusion-associated cancer recurrence and infection: Meta-analysis of randomized, controlled clinical trials
21. Perioperative allogeneic blood transfusion does not cause adverse sequelae in patients with cancer: A meta-analysis of unconfounded studies
22. The biologic effects of leukocytes present in transfused cellular blood products
23. Blood transfusion and tumor growth in animal models
24. Clinical studies of blood transfusion and cancer
25. Immunomodulatory effects of allogeneic blood transfusions: Clinical manifestations and mechanisms
26. Allogeneic blood transfusion-induced enhancement of tumor growth: Two animal models showing amelioration by leukodepletion and passive transfer using spleen cells
27. Growth enhancement of established tumors by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion: The importance of the timing of the leukodepletion
28. Blood transfusion and infection after colorectal cancer surgery
29. Transfusion and postoperative pneumonia in coronary artery bypass graft surgery: Effect of the length of storage of transfused red cells
30. Differences in postoperative infection rates between patients receiving autologous and allogeneic blood transfusion: A meta-analysis of published randomized and nonrandomized studies
31. Multicenter-randomized controlled trials in transfusion medicine
32. A multicenter randomized controlled trial of transfusion requirements in critical care
33. Cutaneous T-cell lymphoma: A model for selective immunotherapy
34. Tumor-specific peptides in cutaneous T-cell lymphoma: Association with class I major histocompatibility complex and possible deviation from clonotypic T-cell receptor
35. Dendritic cell/peptide cancer vaccines: Clinical responsiveness and epitope spreading
36. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8+ Fas(CD95)+ T lymphocytes
37. Soluble HLA class I, HLA class II and FAS ligand in blood components: A possible key to explain the immunomodulatory effects of allogeneic blood transfusions
38. Genomic amplification of a decoy receptor for FAS ligand in lung and colon cancer
39. Death receptors: Signaling and modulation
40. Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: Frequent long-term microchimerism in severe trauma patients
41. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis
42. Fetal DNA in skin of polymorphic eruptions of pregnancy
43. The power of primers
44. Detection of microchimerism by PCR is a function of amplification strategy
45. Transient increase in circulating donor leukocytes after allogeneic transfusion in immunocompetent recipients compatible with donor cell proliferation
46. Rules of evidence and clinical recommendations on the use of antithrombotic agents
47. Implications of human trophoblast karyotype for the evidence-based approach to the understanding, investigation, and treatment of recurrent spontaneous abortion
48. Trials and tribulations in the treatment of recurrent spontaneous abortion
49. Worldwide collaborative observational study and meta-analysis on allogeneic leukocyte immunotherapy for recurrent spontaneous abortion
50. The use of allogeneic leukocytes or IV IgG for the treatment of patients with recurrent spontaneous abortions
51. Mononuclear-cell immunization for prevention of recurrent miscarriages: A randomized trial
52. Other immunomodulatory effects of blood transfusion
53. Perioperative blood transfusion does not prevent recurrence in Crohn's disease
54. Treatment of rheumatoid arthritis by immunization with mononuclear white blood cells: Results of a preliminary trial
55. The influence of a partially HLA-matched blood transfusion on the disease activity of rheumatoid arthritis
56. Camouflaged blood cells: Low-technology bioengineering for transfusion medicine
57. Chemical camouflage of antigeneic determinants: "Stealth" erythrocytes
58. Mechanisms and new approaches for the allogeneic blood transfusion induced immunomodulatory effect
59. Immunotherapy and gene transfer in the treatment of the Oncology patient: Role of Transfusion Medicine
60. The mechanism of apoptosis in human platelets during storage
61. Thrombopoeitin and the TPO receptor during platelet storage
62. Rapid reconstitution of Epstein Barr vires specific T-lymphocytes following allogeneic stem cell transplantation
63. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
64. Extreme leukoreduction of major histocompatibility complex class II positive B cells enhances allogeneic platelet immunity
65. Unique processing pathways within recipient antigen-presenting cells determine IgG immunity against donor platelet MHC antigens
66. Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light
67. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment
68. Viral hyperinfection of the central nervous system and high mortality after hematopoietic stem cell transplantation for treatment of Theilet's murine encephalomyelitis virus-induced demyelinating disease
69. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation
70. Effect of disease stage on clinical outcome after syngeneic bone marrow transplantation for relapsing experimental autoimmune encephalomyelitis
71. Leukoreduced blood components: Laboratory and clinical aspects
72. Bedside filtration of blood products in the prevention of HLA alloimmunization: A prospective randomized trial
73. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions
74. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant
75. Leukocyte-reduction to prevent transfusion-transmitted cytomegalovirus infections
76. Transfusion-associated immunomodulation and universal white cell reduction: Are we putting the cart before the horse?
77. The use of leukocyte reduced blood components
78. Possibility to improve preservation of whole blood by leukocyte depletion before storage
79. New variant Creutzfeldt-Jakob disease (nvCJD): The risk of transmission by blood transfusion and the potential benefit of leukocyte-reduction of blood components
80. Adoptive immunotherapy with donor lymphocyte transfusions
81. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
82. Hypotension and bedside leukocyte reduction filters
83. Leukocyte reduction filter problems
84. Transfusion-associated red eye syndrome